Valuation
- Market cap
- 26,621,000
- Revenue TTM
- $0
- Net income TTM
- $-96,940,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 70,300
- Avg volume
- 1,298,442
- Day's range
- $6.62 – $7.35
- Shares out
- 3,944,000
- Stochastic %K
- 25%
- Beta
- 2.79
- Analysts
- Hold
- Price target
- $4.00
Company profile
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclini...
Show more
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 425 620 8501
- Website
- https://www.athira.com
- Address
- 18706 North Creek Parkway, Suite 104, Bothell, United States
Latest news
No headlines yet.
